* Lexicon Pharmaceuticals Inc LXRX.OQ reported a quarterly
adjusted loss of 18 cents per share for the quarter , higher
than the same quarter last year, when the company reported EPS
of -21 cents. The mean expectation of six analysts for the
quarter was for a loss of 16 cents per share. Wall Street
expected results to range from -18 cents to -15 cents per share.
* Revenue rose 980.2% to $1.75 million from a year ago;
analysts
expected $2.93 million.
* Lexicon Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 18 cents.
* The company reported a quarterly loss of $64.81 million.
* Lexicon Pharmaceuticals Inc shares had fallen by 19.1%
this
quarter and lost 17.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 4.2%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Lexicon
Pharmaceuticals Inc is 5.00
This summary was machine generated from LSEG data November 12 at
11:26 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.16 -0.18 Missed
Jun. 30 2024 -0.19 -0.17 Beat
Mar. 31 2024 -0.20 -0.20 Met
Dec. 31 2023 -0.22 -0.20 Beat